INTRODUCTION:

Stem cells are the body's building blocks. These are the cells that give rise to all other cells with specific functions. Stem cells have the ability to grow and differentiate into 200 different types of human cells. The estimated 30 trillion cells that make up the human body make stem cells crucial to human growth. Scientific studies as well as thousands of clinical trials are looking into the potential of stem cells to cure human ailments. These cells are giving many people throughout the world hope, including patients, researchers, and clinicians.

The leading cause of death in the world is cancer^1,2,3. While the prevalence of infectious diseases has dramatically decreased over the past few decades, leukemia and solid tumors have demonstrated to have an increasing prevalence overall⁴.

The majority of treatments use potent cytotoxic chemicals to attack particular uncontrolled components in an effort to reduce tumor survival and cell growth^5,6. Cancer adapts to hostile surroundings and can endure therapeutic management due to its quick reproduction capability and continual mutations. The ability of cancer cells to proliferate and, in many cases, survive is due to their stemness^7,8. Thus, developing more potent treatments may be made possible by understanding how cancer cells acquire and evolve resistance.

Traditional surgical or chemo-radiotherapeutic methods typically cannot eradicate metastatic cancer cells, and disease recurrence is very common after treatment. In contrast hand, stem cell-based medicines are becoming more and more effective at treating cancer. By homing in on and concentrating on both primary and metastatic tumor foci, stem cells can serve as innovative delivery systems. Stem cells that have been engineered to consistently express several cytotoxic medicines decrease tumor growth and increase lifespan in preclinical animal models.

Additionally, stem cells can be used in immunotherapy, cancer stem cell-targeted therapy, and applications for anticancer drug screening. Although it is technically possible to use stem cells to treat human tumors, issues like treatment durability and tumorigenesis demand for more research in order to enhance therapeutic efficacy and applicability.

Cancer is a leading cause of death in both developed and developing countries, and is an increasing medical burden worldwide, due to population growth and ageing. Chemotherapy, fractionated radiation, and surgical resection are the main cancer treatments. However, the effectiveness of many therapeutic choices is constrained by treatment-related adverse effects, off-target effects, and drug resistance. Additionally, conventional medicines typically are unable to eradicate cancer cells that have spread to other parts of the body, making recurrence highly likely. As a result, scientists are attempting to create novel, efficient medicines with minimal to no damage in normal cells.

Chronologic illnesses like cancer pose a major threat to human existence. For the treatment of cancer, a variety of methods have been devised, including surgery, radiotherapy, chemotherapy, and targeted therapy. Because of all these treatments, the incidence rate of cancer has been steady in women and has somewhat decreased in males during the previous ten years (2006 -2015), and the death rate from cancer has also decreased over the same period (2007 - 2016). However, only some malignant tumors can be effectively treated with conventional cancer therapies.

CSCs were first identified in leukemia and then isolated via CD34+ and CD38− surface marker expression in the 1990s.^9,10,11CSCs expressing different surface markers, such as CD133, nestin, and CD44, have been subsequently found in many nonsolid and solid tumors, and these cells also form the bulk of the tumor^.12,13 CSCs can generate tumors via the self-renewal and differentiation into multiple cellular subtypes.¹²The activities of CSCs are controlled by many intracellular and extracellular factors, and these factors can be used as drug targets for cancer treatment.¹⁵It is currently believed that CSCs are the key "seeds" for tumor initiation and development, metastasis, and recurrence.¹⁶ CSCs have evolved and are highly heterogeneous.¹⁷Breast CSCs have different expression patterns of surface biomarkers, such as CD44+, CD24−, SP, and ALDH+^18,19,20CD271− or CD271+ melanoma stem cells can form tumors in SCID mice.¹⁹The heterogeneity of CSCs has also been found in other cancers, including glioblastoma,²² prostate cancer,²³ and lung cancer.²⁴ The heterogeneity of CSCs is so complex that more effective biomarkers are needed to identify CSCs or distinguish the heterogeneity of CSCs.

Because of their special abilities to migrate toward cancer cells, secrete bioactive substances, and suppress the immune system, stem cells can more effectively target tumors and get over present barriers to gene therapy. Preclinical stem cell-based approaches have a lot of potential for usage in specific cancer therapeutic applications. However, there are still issues with stem cell therapies from a scientific standpoint, and further research is required to confirm preclinical results. This review lists the benefits, possibilities, and potential difficulties of recent investigations on anti-cancer stem cell therapy.

Structure of stem cell:

In addition to their capacity for self-renewal and differentiation, stem cells contain migratory, immunosuppressive, and anticancer activities. Stem cells can be modified to both evade the host immune response and function as cellular delivery systems because they express growth factors and cytokines that control host innate and cellular immunity pathways^24,25Additionally, stem cells have the ability to physically engage with tumor cells and secrete substances like CCL2/MCP-1 that alter the phenotypes of co-cultured tumor cells and have intrinsic anticancer effects^26,27.

Types of stem cells:

Stem cells are a distinct population that can self-renew indefinitely, produce clonal cell populations from single cells, and specialize into multiple cell types ²⁸. Tissue regeneration and homeostasis depend heavily on resident stem cell pools' capacity for self-renewal ²⁹. In general, stem cells can be divided into "embryonic" (ESCs) and "somatic" categories (SSCs). Adult stem cells, also known as SSCs, are multipotent and can differentiate into any type of cell with a particular lineage, such as neural stem cells (NSCs), mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), endothelial progenitor cells (EPCs), and others. SSCs are also referred to as adult stem cells. Cancer stem cells (CSCs) may at least occasionally be responsible for carcinogenesis and disease progression ^{30, 31}

Umbilical stem cells:

The umbilical cords of healthy, live caesarean deliveries are harvested for the stem cells, which are then donated by the mothers. These are by far the most efficient stem cell types now on the market that are obtained ethically. The stem cells are far more physiologically active and have a better capacity for tissue growth and division than older stem cells because of their youthful age. The potency of younger stem cells is roughly ten times greater than that of older stem cells. Mesenchymal stem cells and hematopoietic stem cells are the two main stem cell types seen in umbilical cord blood. This makes it possible to treat a wide range of illnesses and ailments.

Placental stem cells:

These are similar to umbilical cord derived stem cells and are obtained in the same manner, but are extracted from placental tissue rather than the umbilical cord.

Amniotic fluid stem cells:

The fluid in which a newborn infant resides while a woman is pregnant is called amniotic fluid. There are a small number of stem cells floating in the fluid that enable the normal growth of a developing baby. Additionally, there are a wide variety of bioactive chemicals that support tissue growth. Because it includes the fewest stem cells, this type of stem cell therapy is the least expensive one that is also the least efficient. The greatest candidates for amniotic fluid stem cell therapy are those with very mild degenerative disorders or those who need additional care to an umbilical cord derived stem cell therapy to hasten tissue regeneration.

PRP (Placental Rich Plasma):

The patient being treated peripheral blood is used to create Platelet Rich Plasma (PRP). PRP has a modest quantity of stem cells, but the injection's bioactive chemicals are mostly responsible for its ability to heal. PRP procedures typically cost $500 to $2,000 per joint. PRP treatments are complimentary with all of our stem cell treatments at the Stem Cell Rejuvenation Center. For individuals with milder illnesses or those who would prefer a less expensive option, we also offer PRP treatments separately from stem cell therapies.

Neural stem cells:

Expression of nestin, Sox2, and other traditional markers, as well as expansion in culture medium rich in epidermal and fibroblast growth factors, are characteristics of NSCs^32,33,34. NSCs have been widely used to treat brain, breast, prostate, and lung malignancies because they can self-renew and differentiate into astrocytes, neurons, or oligodendrocytes.

ESC [embryonic stem cells]:

As pluripotent cells, ESCs can differentiate into all cell types except those in the placenta³⁵, and are therefore used as gold standards in the evaluation of all pluripotent cells cultured in vitro. Applications for ESCs in scientific research and human clinical trials are constrained, nonetheless, because of ethical issues. Because iPSC creation does not necessitate the death of embryos, ESCs can be substituted by induced pluripotent stem cells (iPSCs) reprogrammed from adult somatic cells (such as skin fibroblasts) via forced expression of pluripotency factors³⁶. iPSCs are similar to ESCs but do not have immunogenic or ethical restrictions, making them potentially more useful in clinical settings.

Since ESCs have higher totipotency and an unlimited life span compared to ASCs, which have lower totipotency and a shorter life span, they are the ideal source of stem cells for therapeutic uses. The use of ESCs is however subject to ethical limitations (Department of Health, UK, National Institutes of Health, and International Society for Stem Cell Research), and its use for research and therapeutic purposes is restricted³¹ and outright forbidden in many nations throughout the world. Additionally, studies on mice have demonstrated that increased totipotency stem cells are more tumorigenic³⁷. ASCs are the stem cells that are used for research and therapy the most frequently because they are the easiest to get and have less ethical restrictions. The ease of accessibility of ASCs versus ESCs is another factor in their adoption. ASCs from bone marrow (HSCs & MSCs) are the stem cells that have been investigated the most, according to the literature³⁸. Supporting HSCs in the bone marrow, MSCs have the capacity to develop into a variety of mesenchymal cells, including bone, cartilage, fat, muscle, tendon, and marrow stroma, both in vivo and in vitro³⁹

ESCs are made from human pre-implantation embryos that are five days old, however there is a chance. Numerous tissues, including bone, synovium, adipose tissue, brain, blood vessels, blood, and umbilical cord blood, can yield ASCs^40,41,42,43. ASCs continue to be the primary complement to the stem cells because the use of ESCs is constrained for ethical and legal reasons in research and clinical settings. ASCs can be purchased from a number of websites, but the best source has not yet been identified. ASCs are most frequently obtained from peripheral blood and bone marrow. One of the frequent methods used to extract ASCs is the bone marrow (BM) aspiration, although it has a risk of morbidity in the form of sepsis complications and wound infections⁴⁴. In addition to bone marrow aspiration, ASCs can also be extracted from adipose tissues, such as abdominal fat and infra-patellar fat^30,36. This method is less invasive and morbid than bone marrow aspiration. It has been demonstrated that there are no appreciable differences in the kinetics of cell growth, cell senescence, adherent stromal cell gene transduction, or the yield of stem cells isolated from bone marrow or adipose tissues⁴⁵. Peripheral blood also offers a risk-free, simple, and morbidity-free method for isolating ASCs. Use of ASCs through peripheral blood has shown to induce more T and NK (Natural Killer) cells compared to bone marrow ASCs⁴⁶. Recently, the stem cells have been claimed to be obtained from the amniotic fluid without any harm to mother and embryo (posted on cnn.com on 08/01/2007)

Mesenchymal stem cells:

MSCs come from the connective tissue or stroma that surrounds the body’s organs and other tissues. MSCs have been employed by researchers to produce new bone, cartilage, and fat cells as well as other bodily tissues. They might one day assist in resolving a variety of medical issues.

Induced pluripotent stem cells:

Scientists create these in a lab, using skin cells and other tissue-specific cells. These cells exhibit behaviors resembling those of embryonic stem cells, making them potentially valuable for creating a variety of treatments. However, additional study and development are required.

Use of embryos for stem cells:

A human blastocyst is destroyed when embryonic stem cells are used, and a fertilized egg cannot develop into a person as a result.

These days, scientists are investigating for non-embryonic methods of producing or using stem cells.

A line of embryonic stem cells has practically limitless potential for development. These cells might be utilized to develop organs, heal tendons and ligaments, stop tissue damage, cure cancer, terminate diseases like Alzheimer's or Parkinson's, and much more because they could be activated to become any sort of cell in the body. These lines have a considerably greater future potential than even adult stem cells for treatment since they can divide into particular cells and keep developing.

Adult stem cells:

Adult stem cells can be removed from bone marrow, fat, or blood with little negative impact on the patient. This puts an end to the debate about the destruction of life. A human embryo is not destroyed in the process of obtaining cells; they can be collected directly from the tissue to which they belong.

How stem cell therapy works^47,48:

Sources of stem cell:

Embryos and adult bodily tissues are the two main sources of stem cells. Researchers are also experimenting with genetic "reprogramming" methods to create stem cells from different types of cells.

Different types of tissue contain stem cells. Scientists have discovered stem cells in various tissues, such as:

· The brain

· Bone marrow

· Blood and blood vessels

· Skeletal muscles

· Skin

· The liver

The bone marrow or peripheral blood are the two most frequent sources of stem cells. While the process for isolating PBSCs is far less intrusive and morbid, the bone marrow aspiration operation is invasive and linked to potential consequences include fracture, wound infection, and sepsis. In comparison to bone marrow-derived stem cells, PBSCs have been demonstrated to produce more CD4 T and NK cells⁴². As a result, peripheral blood stem cells (PBSCs) are regarded as the preferred source of stem cells; yet, several clinical research have made contentious conclusions when comparing PBSCs and BM stem cells public. It is also noticed that the occurrence of graft versus host reaction varies with PBSCs compared to BM stem cells^49,50.

Because adult stem cells can execute an autologous transplant, the immune system of the body does not reject them. When organs, tissues, or cells are transplanted from one person to another, the recipient's body frequently rejects the tissue or organ provided by the donor because their immune system identifies it as a foreign thing and will attack it as if it were a disease. After that, the recipient must take medication for the remainder of his or her life to combat this rejection potential treatments include regenerating bone using cells derived from bone marrow stroma, creating insulin-producing cells to treat type 1 diabetes, and using cardiac muscle cells to restore damaged heart muscle after a heart attack. They have the capacity to differentiate into pluripotent stem cells, which enables them to enjoy the benefits of embryonic cells without requiring the destruction of human embryos.

Cancer that affect the bone marrow:

While certain tumors cannot travel to the bone marrow, others can originate there. When cancer targets the bone marrow, it either causes it to produce cells that are unhealthy and don't function properly, or too many of some cells that push out other cells.

Leukemias, multiple myelomas, and lymphomas make up the majority of malignancies that interfere with bone marrow function. These malignancies all develop in blood cells. There are other malignancies that can spread to the bone marrow and impact blood cell production.

A stem cell transplant may be a crucial component of therapy for some forms of leukaemia, lymphoma, and multiple myeloma. The purpose of the transplant is to remove the cancerous cells as well as any unhealthy or damaged cells that aren't functioning properly, and to provide the patient with fresh, healthy stem cells so they may "start over."

How a stem cell transplant works to treat cancer:⁵¹

When cancer or the chemotherapy, radiation, or other treatments used to treat the cancer have killed bone marrow cells, stem cell transplants are utilized to replenish those cells.

Different types of stem cell transplantation exist. To destroy cancer cells, they all employ very high doses of chemotherapy (often in combination with radiation). The bone marrow may temporarily stop producing blood cells as a result of the high doses, which can also kill all the patient's stem cells. In other words, a person's entire stock of embryonic stem cells is systematically eliminated. But because blood cells are essential for our bodies to operate, stem cell transplants can help. By replenishing the body's stem cells that have been lost due to treatment, the transplanted stem cells assist in "rescuing" the bone marrow. Therefore, transplanting the healthy cells enables medical professionals to administer far larger chemo doses in an effort to eradicate all cancer cells, and the stem cells can develop into healthy, mature blood cells that function normally and procreate cancer-free cells.

If a stem cell transplant uses stem cells from another person, there is an additional way for it to function (not the cancer patient). In certain circumstances, the transplant may aid in the treatment of particular cancers in a manner other than just replacing stem cells. In many cases, donated cells are more effective at locating and eliminating cancerous cells than the patient's own immune system ever was. The "graft-versus-cancer" or "graft-versus-leukemia" effect is what causes this. The given cells serve as the "graft." The result is that some transplants, in addition to saving bone marrow and enabling the development of normal blood cells from stem cells, actually assist in killing off the cancer cells.

To make the treatment more effective, in conjunction with stem cells, the Insulin Potentiation Therapy (IPT) method is used. It is a low-dose chemotherapy treatment that is secure for treating cancer. The IPT potentiation method is a tried-and-true technique we employ at hospitals like The Holistic Sanctuary to treat cancer in a more humane way. It provides favorable outcomes in cases of colon and lung cancer and has produced favorable outcomes in cases of other cancers and other disorders.

Dendritic cell immunology:⁵²

This type of stem cell treatment for cancer is very reliable for the autologous cellular procedure, using elements for stopping the cancer cells faster than other conventional therapies. With this type of method, there’s no more need for chemotherapy, so the toxic effects of chemo are avoided.

Unlike other therapies used to treat cancer, there is no risk of rejection or complications as the method is done with autologous stem elements. It’s a natural method that eliminates the risks for side effects and toxicity associated with chemotherapy.

What type of cancer can be cured by stem cell therapy:

Numerous aggressive malignancies, including colon and lung cancer as well as other cancers, will develop as a result. It seems that 75% of patients undergoing allogeneic stem cell transplants survived after the first year, and the anticipated rate of survival is a bit over 60%.

General mechanism:⁵³

The stem cell therapy will work to maximize the immune system's capacity to fight cancers. The development of antigen-specific immunotherapy was aided by the antigens unique to malignancy. The body receives antigen and adjuvant to therapeutic T lymphocytes through dendritic cell vaccination. The natural agent to transport antigens has been identified as DCS. They provide the amazing capacity to modulate immunity and immunological tolerance, making them crucial for research into cancer treatments. Because of this, DCS is crucial for enhancing cancer protection.

Dendritic stem cell therapy may not be appropriate for all patients since medical background and requirements must be met. The experts at Holistic Sanctuary will determine if you are an appropriate candidate for the operation.

Patients in stage 4 get remarkable outcomes from the dendritic stem cell procedure. No matter what stage of metastasis a tumor is in, immunotherapy will combat it.

We should also stress that the dendritic cell strategy works best in conjunction with therapies like heat. The patients who are enrolled should undergo two weeks of intensive chemotherapy after the dendritic surgery.

Stem cell transplants cost a lot, and some types cost more than others. For example, getting a donor's cells costs more than collecting your own cells. And, different drug and radiation treatments used to destroy bone marrow can have high costs. Cost can be impacted by which transplants need to stay in the hospital for longer than others. Stem cell transplants can cost hundreds of thousands of dollars, notwithstanding the distinctions.Some cancers, particularly those with solid tumors, are still deemed experimental, therefore insurers could not pay the cost of a transplant (or specific types of transplants).

To assist patients, their families, and friends in raising funds for all kinds of stem cell transplants in the US, the National Foundation for Transplants (NFT) offers fund-raising advice. Call 1-800-489-3863 or visit www.transplants.org to get in touch with them.

1. There is little rejection of adult stem cells.

Adult stem cells obtained from each patient can be used to create treatments. Since the cells are obtained from the person who needs therapy, they can then be used to create a variety of medicines with a low risk of rejection. Rejection rates are quite low, even when well-known umbilical cord blood cells are used to create treatments. This limits the need for immunosuppressant treatments to maintain a positive quality of life in the future.

2. A few types of stem cells can develop into pluripotent stem cells:

Pluripotent stem cells can be created from adult stem cells by reprogramming them with iPS reprogramming factors. They can then be triggered into mesoderm, endoderm, or ectoderm cells after this has happened. This procedure enables the potential advantages that embryonic stem cell lines could offer for medicinal treatments without necessitating the destruction of embryos in order to gather the necessary cells.

3. There are various stem cell therapies available today:⁵⁴

Currently, bone marrow transplantation is used to treat leukemia and lymphoma patients using stem cell treatment. Prochymal, a stem cell treatment, has received conditional approval in Canada to treat children with graft vs. host disease. This research elaborates us about how human life functions.

We are able to comprehend how the cells in our bodies function because to stem cell research. It is possible to comprehend the progression of a sickness or illness by having a better understanding of these processes. Even if a stem cell therapy is not created as a result of this research, the knowledge gained can be used to develop new treatments that may be able to reverse the damage being done to our cells. This enables us to raise the average life expectancy, halt sickness, and even lower the price of medical care.

Drawback:

The main drawback is we currently do not have exact idea that how stem cell works, May be there are long term health effects that we are not aware about this therapy have high rejection rate because stem cells are derived from foreign body so therapy may not always be successful. Since stem cell therapy has been the subject of much debate, research on embryonic stem cells has faced strong hostility from both the general public and religious organizations. Since only embryonic stem cells are flexible enough to mend damaged nerves, organs, and tissues, as well as to treat hundreds of lethal diseases, some people think that there is a lot of potential in this field of research. On the other hand, many people defend their positions against stem cell research and think it is profoundly unethical, if not deadly, to destroy a human embryo in the hopes of one day discovering a cure or aiding someone in need.

Every year, tens of thousands of patients have stem cell transplants, and the number of ailments and disorders that can be successfully treated with them increases. Even though short-term improvements are being observed, we do not yet know if such medicines have long-term repercussions. The success of stem cell research and therapies is currently the subject of more than 3,500 distinct research investigations, although the findings are still awaited.

Arguments about stem cell therapy:

1. Embryonic stem cell research is an expensive and unethical means to advance science; it diverts resources from more moral and fruitful research initiatives.

2. Adult stem cells are much more successful than embryonic stem cells in treating disease-affected tissue because the latter may be rejected by the body or later grow into a tumor mass.

3. The argument that embryonic stem cells are unstable and might, at the DNA level, carry the risk of genetic diseases in themselves is another strong argument against stem cell research.

4. Treatments using stem cells have not been properly investigated, and they may lead to the evolution of severe diseases that are still undiscovered by humanity.

5. To justify the cost of a human embryo, various animal research in stem cell therapy have shown to be unsuccessful and risky.

6. Destruction of a human embryo, that has a potential to grow into a baby, is necessary to receive a portion of stem cells, which is inhumane in itself.

7. Stem cells for research can be successfully obtained from other sources like umbilical cord stem cells, amniotic fluid or adult stem cells.

8. Another important viewpoint of cons of stem cell research is that by allowing therapeutic cloning or genetic engineering of human organs, tissues or embryos we open up a door to research programs with devastating consequences

9. One of the other important arguments against stem cells research is that there has been virtually no real successful cure or even a potential for cure found to support There is no proof that destroying a human embryo will help anyone; doing so amounts

10. The final objections against stem cell research center on the fact that such treatments are simply too expensive to be used widely.

CONCLUSIONS:

Stem cells play an essential role in the cure of cancer, and dendritic cell immunotherapy is the most notable approach to date. It is a highly effective autologous stem cell therapy for cancer that utilizes dendritic, natural killer, and lymphokine-activated killer (LAK) cells (NK cells). They will stop and eradicate the blood-borne malignant cancer cells faster than the standard of care, without the use of harmful chemotherapy.

· The stem cell therapy in market is blooming

· These days more and more clinics are offering these type of treatment

· Researchers are now studying stem cells to see if they could help treat a variety of conditions that impact different body systems and parts.

· Stem cells are vital for regeneration in some tissues because they can multiply quickly to replace damaged or dead cells. Scientists believe that knowing how stem cells work can help treat damaged tissue ⁴⁵

· There is also a great deal of potential

· It can help in progress of cancer research because these are similar to cancer cells. they can produce themselves indefinitely

ACKNOWLEDEMENT:

The authors would like to thank the institute for all the facility support.

CONFLICTS OF INTEREST:

The authors declare no conflict of interest.

REFERENCES:

1. Siegel RL, Miller KD, Jemal A. Cancer statistics. 2016, CA Cancer Journal for Clinicians. 2016; 66(1): 7–30.

2. Torre LA, Siegel, RL, Ward EM., Jemal A. Global cancer incidence and mortality rates and trends an update, Cancer Epidemiology, Biomarkers and Prevention. 2016; 25(1):16–7.

3. Balaji EV, Selvan AT. Cancer-A Historical Status, Government Regulation and Current Scenario of Socio-Economic Impact – Retrospective Study. Asian J. Pharm. Res. 2018; 8(3): 133-5. doi: 10.5958/2231-5691.2018.00023.0

4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Medicine 2006; 3(11).

5. Coates AS, Winer EP, Goldhirsch A et al. Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.Annals of Oncology. 2015; 26(8): 1533–6.

6. Kumbhar S, Salunkhe V, Magdum C. Targeted Drug Delivery: A Backbone for Cancer Therapy. Asian J. Pharm. 2013 3(1): 40-46.

7. Colak, Medem JP. Cancer stem cells—important players in tumor therapyresistance. FEBS Journal.2014; 281(21):4779–1.

8. Moore N, Lyle S. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. Journal of Oncology.2011; 2011:11 ID 396076.

9. Lapidot T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994).

10. Bonnet D, Dick JE.Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737 (1997).

11. Dange VN, Shid SJ, MagdumCS, Mohite SK. A Review on Breast cancer: An Overview. Asian J. Pharm. 2017; 7(1): 49-1. doi: 10.5958/2231-5691.2017.00008.9

12. Lapidot T. et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367, 645–648 (1994).

13. Saloni S. Chhajed, Mayuri V. Mali, Azam Z. Shaikh, S. P. Pawar, Ritik. S. Jain. Cancer: Immunology and Immunotharapy. Research Journal of Pharmacology and Pharmacodynamics.2022; 14(3):159-4. doi: 10.52711/2321-5836.2022.00027

14. Kunal D. Sutar, Rutika D. Harshad, Omkar S. Sangar, Aishwarya C. Patil, Santosh A. Payghan. An Overview of Stem Cell Therapy. Research Journal of Topical and Cosmetic Sciences. 2022; 13(1):21-6. doi: 10.52711/2321-5844.2022.00004

15. Selvi,S. Stem Cell Therapy. Int. J. Adv. Nur. Management. 2017; 5(4): 361-4. doi: 10.5958/2454-2652.2017.00077.4

16. Ajani JA, Song S, Hochster H S, Steinberg IB. Cancer stem cells: the promise and the potential. Semin. Oncol. 42(Suppl. 1), S3–S17 (2015).

17. Cojoc M, Mabert K, Muders MH, Dubrovska A. A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms, Semin. 2015; 31: 16–27.

18. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res. 22, 457–472 (2012).

19. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke M F Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983–3988 (2003).

20. Ginestier C. et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1: 555–7.

21. Hirschmann-Jax C. et al. A distinct side populationof cells with high drug efflux capacity in human tumor cells. Proc. Natl Acad. Sci. USA 101, 14228–14233 (2004).

22. Quintana E, et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell . 2010; 18:510–523.

23. Singh SK, et al. Identification of human brain tumor initiating cells. Nature 432, 396–401 (2004).

24. Van den Hoogen C. et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res. 70, 5163–5173 (2010).

25. Zhang WC. et al. Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 148, 259–272 (2012).

26. Bernardo ME, Fibbe WE. Mesenchymal stromal cells: sensors and switchers of inflammation. CellStem Cell. 2013; 13:392–402.

27. Milwid JM, Elman JS, Li M, Shen K, Manrai A, Gabow A, Yarmush J, Jiao Y, Fletcher A, Lee J, Cima MJ, Yarmush ML, Parekkadan B. Enriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators. Mol Ther. 2014; 22: 999–1007.

28. Motaln H, Gruden K, Hren M, Schichor C, Primon M, Rotter A, Lah TT. Human mesenchymal stem cells exploit the immune response mediating chemokines to impact the phenotype of glioblastoma. Cell Transplant. 2012; 21: 1529–1545.

29. Tiwari RK, Sharma V, Pandey R, Shukla SS. Stem Cells: Basics and its Prospective uses in Medical field. Research J. Pharm. and Tech 2018; 11(4): 1530-1534. doi: 10.5958/0974-360X.2018.00285.

30. Tran C, Damaser MS. Stem cells as drug delivery methods: application of stem cell secretome for regeneration. Adv Drug Deliv Rev. 2015;82–83:1–11.

31. Seita J, Rossi DJ, Weissman IL. Differential DNA damage response in stem and progenitor cells. Cell Stem Cell. 2010;7:145–147.

32. Lin HT, Otsu M, Nakauchi H. Stem cell therapy: an exercise in patience and prudence. Philos Trans R SocLond B Biol Sci. 2013;368:20110334.

33. Kumari R. Stem Cell. Int. J. Nur. Edu. and Research. 2018; 6(4):443-446. doi: 10.5958/2454-2660.2018.00107.2

34. Kanojia D, Balyasnikova IV, Morshed RA, Frank RT, Yu D, Zhang L, Spencer DA, Kim JW, Han Y, Yu D, Ahmed AU, Aboody KS, Lesniak MS. Neural stem cells secreting anti-her2 antibody improve survival in a preclinical model of her2 overexpressing breast cancer brain metastases. Stem Cells. 2015;33:2985–2994.

35. HJ, Doo SW, Kim DH, Cha YJ, Kim JH, Song YS, Kim SU. Cytosine deaminase-expressing human neural stem cells inhibit tumor growth in prostate cancer-bearing mice. Cancer Lett. 2013;335:58–65.

36. Weiss L, Or R, Slavin S, Naparstek E, Reich S, Abdul-Hai A. Immunotherapy of murine leukemia following non-myeloablative conditioning with naive or G-CSF mobilized blood or bone marrow stem cells. Cancer Immunother. 2004;53:358–2. doi: 10.1007/s00262-003-0440

37. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. 2006; 126: 663 6.

38. Bago JR, Sheets KT, Hingtgen SD. Neural stem cell therapy for cancer. Methods. 2016; 99: 37–3.

39. Serakinci N, Guldberg P, Burns JS, Abdallah B, Schrodder H, Jensen T, Kassem M. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene. 2004; 23: 5095–5098. doi: 10.1038/sj.onc.1207651.

40. Huang JI, Zuk PA, Jones NF, Zhu M, Lorenz HP, Hedrick MH, Benhaim P. Chondrogenic potential of multipotential cells from human adipose tissue. PlastReconstr Surg. 2004; 113:585–594. doi: 10.1097/01.PRS.0000101063.27008.E1.

41. Simonsen JL, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan SI, Jensen TG, Kassem M. Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol. 2002; 20:592–596. doi: 10.1038/nbt0602-592.

42. Awad HA, Wickham MQ, Leddy HA, Gimble JM, Guilak F. Chondrogenic differentiation of adipose-derived adult stem cells in agarose, alginate, and gelatin scaffolds. Biomaterials. 2004; 25:3211–2. doi: 10.1016/j.biomaterials.2003.10.045.

43. Lee OK, Kuo TK, Chen WM, Lee KD, Hsieh SL, Chen TH. Isolation of multipotentmesenchymal stem cells from umbilical cord blood. Blood. 2004; 103:1669–5. doi: 10.1182/blood-2003-05-1670.

44. Miura M, Gronthos S, Zhao M, Lu B, Fisher LW, Robey PG, Shi S. SHED: stem cells from human exfoliated deciduous teeth. ProcNatlAcadSci U S A. 2003; 100:5807–2. doi: 10.1073/pnas.0937635100.

45. Sottile V, Halleux C, Bassilana F, Keller H, Seuwen K. Stem cell characteristics of human trabecular bone-derived cells. 2002;30:699–704. doi: 10.1016/S8756-3282(02)00674-9.

46. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143–147. doi: 10.1126/science.284.5411.143.

47. De Ugarte DA, Morizono K, Elbarbary A, Alfonso Z, Zuk PA, Zhu M, Dragoo JL, Ashjian P, Thomas B, Benhaim P, Chen I, Fraser J, Hedrick MH. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs. 2003;174:101–109. doi: 10.1159/000071150.

48. Talmadge JE, Reed E, Ino K, Kessinger A, Kuszynski C, Heimann D, Varney M, Jackson J, Vose JM, Bierman PJ. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant. 1997;19:161–172. doi: 10.1038/sj.bmt.1700626.

49. https://r.search.yahoo.com/_ylt=Awr92Ww2hUNjcKsxrkVXNyoA;_ylu=Y29sbwNncTEEcG9zAzMEdnRpZANMT0NVSTA1NF8xBHNlYwNzcg--/RV=2/RE=1665398198/RO=10/RU=https%3a%2f%2fhsci.harvard.edu%2fstem-cells-and-cancer/RK=2/RS=.l0q6ICD1YxyvMiPKXEEUwH.Z.0-

50. Diksha, Sazal Patyar. Role of Stem Cells in treatment of different Diseases. Research J. Pharm. and Tech 2018; 11(8): 3667-3678. doi: 10.5958/0974-360X.2018.00674.1

51. Storek J, Dawson MA, Storer B, Stevens-Ayers T, Maloney DG, Marr KA, Witherspoon RP, Bensinger W, Flowers ME, Martin P, Storb R, Appelbaum FR, Boeckh M. Immune reconstitution after allogeneic marrow transplantation compared with blood stem cell transplantation. Blood. 2001; 97: 3380–3389. doi: 10.1182/blood.V97.11.3380.

52. Sagar J, Chaib B, Sales K, Winslet M, Seifalian a. Role of stem cells in cancer therapy and cancer stem cells: a review

53. Manjusha P. Yeole, Shailju G. Gurunani, Yogesh N. Gholse. Stem Cell Techniques. Research J. Pharm. and Tech. 2013; 6(3): 304-306.

Received on 12.12.2022 Modified on 30.01.2023

Asian J. Pharm. Res. 2023; 13(4):269-276.

DOI: 10.52711/2231-5691.2023.00049